What is the market share of Glucagon | Key Players & Strategic Developments 2026

What is the Glucagon Market Share?

According to 6Wresearch internal database and industry insights, the Global Glucagon Market is estimated at USD 745 million in 2025, projected to reach USD 1.32 billion by 2032, registering a CAGR of 8.7% between 2026-2032.

This expansion is supported by rising cases of severe hypoglycemia, increasing adoption of emergency glucagon kits, and advancements in ready-to-use formulations. This industry accounted for an estimated market share of nearly 41% within the emergency diabetes treatment segment in 2025.

Key Growth Drivers of the Glucagon Market

• Rising incidence of diabetes and severe hypoglycemic episodes
• Increasing adoption of ready-to-inject and nasal glucagon products
• Growing use of glucagon in clinics, home care, and emergency settings
• Advancements in stable liquid formulations and easy-use delivery systems
• Rising awareness of emergency response for hypoglycemia

Glucagon Market Trends

Glucagon Market is witnessing notable growth with trends such as rising adoption of liquid-stable glucagon formulations that eliminate reconstitution steps. Patients want simpler ways to get their medications, so there is more demand for needle-free and nasal delivery systems. Digital health tools that work with diabetes management platforms are making people more aware of how to use them. More people are interested in multi-dose pens that make it easier to deal with low blood sugar. In addition, glucagon is being used more often in outpatient and home care settings.

Emerging Developments in the Glucagon Market

Glucagon Market is evolving with advancements in recombinant production techniques that improve purity and stability. New developments include next-generation nasal glucagon options with faster onset and easier administration. Companies are investing money into new analogs and glucagon receptor modulators so that they can be used to treat more conditions. Researchers are looking into bihormonal pump systems that combine insulin and glucagon to help people with diabetes manage their condition automatically. Partnerships between drug companies and diabetes tech companies are speeding up the process of coming up with new ideas. Better packaging and integration of devices are making them safer and easier to use in emergencies. Long-acting glucagon formulations are also getting more attention for other metabolic uses.

List of Leading Companies in the Glucagon Market

Some of the leading companies include:

• Eli Lilly and Company
• Xeris Pharmaceuticals
• Zealand Pharma
• Novo Nordisk
• Amphastar Pharmaceuticals
• Fresenius Kabi
• Pfizer Inc.

Frequently Asked Questions About the Market Study (FAQs):